Transitions of Care Pharmacist Services in the Psychiatric Population:

Findings of a
Six-Week Transitions of Care Pilot
at Sharp Mesa Vista Hospital

Nada Abou-Karam, PharmD
PGY-2 Resident Pharmacist in Transitions of Care
Sharp HealthCare and Touro University

Objectives

- Define and Transitions of Care (ToC) and describe
 ToC pharmacist services
- Explain the goals of the ToC pharmacist service at Sharp Mesa Vista
- Quantify and characterize the types of services and interventions performed during a six-week ToC pilot
- Recommend next steps for optimizing medication management around transitions of care

Transitions of Care¹

• "Movement of patients between health care locations, providers, or different levels of care within the same location as their conditions or care needs change."

-National Transitions of Care Coalition

ToC in the Psychiatric Population

- ToC model development and intervention testing
 - Significantly less in mental health vs. general medical care²
- Future readmissions measures and penalties may include psychiatric facilities

Medications and Transitions of Care

- Greater than 50% of documented medication errors occur at three times: admission, transfer, discharge³
- Medication management
 - Key component of Transitions of Care (ToC) initiatives

Medications and Transitions of Care

- ED visits due to ADEs⁴
 - ~89,000 annually due to psychiatric medications
 - ~10% of all adult ADE ED visits
 - ~19% result in hospitalization
 - Excludes: intentional self-harm, drug abuse, withdrawal, non-adherence

Sharp Mesa Vista ToC Pilot

- May 3rd, 2015 June 12th, 2015
 - M & Th: 0700 1530 hrs
 - T,W,F: 0800 1630 hrs
- Senior Behavioral Health Center (SBHC)
 - Formerly Older Adult Persons (OAP) unit
 - Opened May 9th, 2015

Senior Behavioral Health Center



HASD&IC @HASDIC · May 7

Ribbon cutting of Sharp Mesa Vista Hospital's Senior Behavioral Health Center. @sharphealthcare @DaveRobertsSD



4

£7

*

+ 0

View photo

Sharp Mesa Vista ToC Pilot: ToC Pharmacist Workflow

• Inclusion:

- Admitted to SBHC during ToC Pilot
- Exclusion:
 - Same weekend admit + discharge

Patient Selection

Admission

- Medication history interview w/ pt and/or caretaker
- Verification & update of documented home medications

 Daily monitoring: Review of labs, organ function, dosing adjustments, drug interactions

Inpatient

Discharge

- Discharge medication review
- Pt and/or caregiver education
- Follow-up calls high risk & missed discharges

Sharp Mesa Vista ToC Pilot

- PGY-2 ToC Pharmacist activities:
 - Attendance at bi-weekly SBHC Treatment Team
 - Identification of potential drug therapy problems (DTPs)
 - Communication of recommendations to managing clinicians

Sharp Mesa Vista ToC Pilot

- PGY-2 ToC Pharmacist activities (continued):
 - Provision of drug information and drug therapy recommendations as requested by RNs and physicians
 - Provision of educational in-services to RNs and staff

Patients Receiving ToC Service

Eligible SBHC Pts N=48

21/48 (44%)
Complete ToC
Service, Admission to
Discharge

27/48 (56%)

No Discharge Medication Review

18/27 (67%)
Still inpatient*
9/27 (33%)

Transferred/Missed

*At time of data collation

Patient Characteristics (N=48)

Age	
Mean (range)	72.7 (50-91)
≥ 80 yrs - N (%)	10 (20.8%)
< 65 yrs - N (%)	5 (10.4%)
Comorbidities, Mental - N (%)	
Depression	23 (48%)
Generalized anxiety dx.	8 (17%)
Bipolar disorder	14 (29%)
Schizophrenia	10 (21%)
Dementia/suspected dementia - N (%)	15 (31%)
Active substance abuse - N (%)	14 (29%)

Patient Characteristics (N=48)

Comorbidities, Medical - N (%)	
Diabetes Type II	12 (25%)
Hypertension	28 (58%)
Hyperlipidemia	16 (33%)
CAD	7 (15%)
CHF	6 (13%)
Atrial fibrillation	7 (15%)
Stroke	4 (8%)
Medication count at admit	
Mean (range)	8.9 (0-22)
≥ 10 - N (%)	17 (35%)
≥ 15 - N (%)	7 (15%)

Errors Identified Upon Review of Admission Medication History

Medication lists containing ≥ 1 error - N (%)

38/48 (79%)


Errors/list - Mean (range)

5.7 (1-22)

Errors Identified Upon Review of Admission Medication History

	Sharp	Sharp	Sharp Mesa
	Memorial -	Memorial -	Vista -
	CHF	Trauma	SBHC
	N=128 pts	N=40 pts	N=48 pts
Medication lists containing ≥ 1 error - N (%)	91	34	38
	(71 %)	(85 %)	(79 %)
# Errors/list - Mean	3.6	3.3	5.7

Types of Errors Identified



Patient CF: Initial Home Medication List

- amlodipine 5 mg PO daily, HTN
- aspirin 81 mg PO daily, stroke prevention
- clotrimazole 10 mg PO 5x daily, antifungal
- ezetimibe 10 mg PO daily, cholesterol
- gabapentin 100 mg PO BID, peripheral neuropathy
- hydrochlorothiazide 12.5 mg PO daily, HTN
- lamotrogine 100 mg PO BID, mood
- meloxicam 15 mg PO daily, pain
- metroprolol succinate 25 mg PO BID, HTN
- nitrofurantoin 100 mg PO BID, UTI

- olanzapine 5 mg PO QHS, antipsychotic
- pantoprazole 40 mg PO daily, ulcer prevention
- paroxetine 10 mg PO daily, depression
- raloxifene 60 mg daily, osteoporosis osteoporosis
- simvastatin 10 mg PO QHS, cholesterol
- solifenacin 5 mg PO daily, overactive bladder
- valsartan-HCTZ 160-12.5 mg PO daily, HTN
- venlafaxine 75 mg PO daily, depression

Patient CF: Updated Home Medication List

- amlodipine 5 mg PO daily, HTN
- aspirin 81 mg PO daily, stroke prevention
- clotrimazole 10 mg PO 5x daily, antifungal
- ezetimibe 10 mg PO daily, cholesterol
- gabapentin 100 mg PO BID QID, peripheral neuropathy
- hydrochlorothiazide 12.5 mg PO daily, HTN
- lamotrogine 100 mg PO BID, mood
- meloxicam 15 mg PO daily, pain
- Metroprolol succinate tartrate 25 mg PO BID, HTN
- nitrofurantoin 100 mg PO BID, UTI

- olanzapine 5 mg PO QHS BID, antipsychotic
- pantoprazole 40 mg PO daily, ulcer prevention
- paroxetine 10 mg PO daily, depression
- raloxifene 60 mg daily, osteoporosis
- simvastatin 10 mg PO QHS, cholesterol
- solifenacin 5 mg PO daily, overactive bladder
- valsartan-HCTZ 160-12.5 mg PO daily, HTN
- venlafaxine XR 75 mg PO daily, depression
- glipizide 10 mg PO BID, diabetes
- oxybutynin ER 15 mg PO daily, overactive bladder

Patient RA

- HPI: Increasing schizophrenic behavior several weeks including: lighting fires, not sleeping, increasing auditory and visual hallucinations
- Hx: schizophrenia, previous hospitalizations x 4 in past 2.5 months, past suicide attempt, rheumatoid arthritis, hypertension, GERD, allergic rhinitis

Patient RA: Initial Home Medication List

- hydrocodone-acetaminophen 10-325 mg PO Q6H prn, pain
- losartan 100 mg PO daily
- lurasidone 30 mg PO daily, depression
- methotrexate 2.5 mg, 1 tab PO weekly, maintenance treatment 4 tabs
- metoprolol 25 mg PO BID, hypertension
- pantoprazole 40 mg PO daily, GERD
- prednisone 20 mg PO daily, pain

Patient RA: Updated Home Medication List

- hydrocodone-acetaminophen 10-325 mg PO Q6H prn, pain
- losartan 100 mg PO daily, hypertension
- lurasidone 30 80 mg PO daily, depression schizophrenia
- methotrexate 2.5 mg, 1 4 tab = 10 mg PO weekly Q Tuesday, maintenance treatment 4 tabs, rheumatoid arthritis
- metoprolol tartrate 25 mg BID, hypertension
- pantoprazole 40 mg PO daily, GERD
- prednisone 20 5 mg PO daily, pain rheumatoid arthritis
- folic acid 1 mg Qday

Patient RA

- Physician informed of medication history updates
 - Verbal recommendation vs CERNER communication
- Recommended changes made to inpatient orders:
 - Prednisone decreased
 - MTX increased
 - Folic Acid added

Patient RA


- Potential consequences of medication errors:
 - Further exacerbation of schizophrenia w/ prednisone dose increase x 4?
 - Exacerbation of RA with MTX dose decrease by 3/4?
 - If prolonged LOS, increased risk of MTX side effects w/out folic acid?
 - Ex: stomatitis, GI intolerance, bone marrow toxicity, abnormal LFTs

Drug Therapy Problems Identified and Interventions Performed

- 86 potential drug therapy problems (DTPs) identified
 - Avg. 1.8 DTP/patient
 - Post-admission; excludes errors corrected in home medication history

 80/86 (93%) of recommendations to address DRPs accepted

Interventions Performed by Stage of Care



Types of Interventions Performed

Intervention Type	N (%)
Add medication	28 (35%)
Discontinue medication	15 (18.8)
Order lab	12 (15%)
Discontinue duplicate	8 (10%)
Increase dosage	7 (8.8%)
Decrease dosage	7 (8.8%)
Modify instructions	1 (1.3%)
Generate Outpatient Rx	1 (1.3%)
Discontinue Outpatient Rx	1(1.3%)

Example "Depart" Problems Identified

- Mismatches between "depart" patient instructions and Rxs
 - Most common: Rx medication present on depart, no Rx
- Omissions of indicated home medications
 - Example resultant ADE:
 - Episodes of hypertensive urgency throughout patient stay
 - Potential ADE avoided by medication restart:
 - Hypertensive emergency, possible stroke postdischarge

Example "Depart" Problems Identified

- Unintentional omissions of new medications initiated during inpatient stay
 - Example:
 - Thiamine, folic acid, and MVI in recent Wernicke's encephalopathy
 - Potential ADE avoided by medication continuation:
 - Irreversible neurological damage

Duplicate Therapy & Conflicting Instructions

Final Med List aspirin (aspirin 81 mg oral delayed release tablet) 1 Tablet(s), Oral, DAILY aspirin 81 Miligram, Oral, DAILY, Indication: cardiac benztropine (benztropine 1 mg oral tablet) 1 Tablet(s), Oral, 3 TIMES A DAY benztropine 1 Miligram, Oral, 3 TIMES A DAY, Indication: mood busPIRone (busPIRone 5 mg oral tablet) 1 Tablet(s), Oral, 2 TIMES A DAY busPIRone 5 Milligram, Oral, 3 TIMES A DAY, Indication: mood clopidogrel (clopidogrel 75 mg oral tablet) 1 Tablet(s), Oral, DAILY clopidogrel 75 Miligram, Oral, DAILY, Indication: prophylaxis docusate (docusate 10 mg/mL oral liquid) 10 Mililiter, Oral, AT BEDTIME docusate 250 Miligram, Oral, AT BEDTIME, Indication: constipation fenofibrate (fenofibrate 145 mg oral tablet) 1 Tablet(s), Oral, DAILY fenofibrate 145 Miligram, Oral, DAILY, Indication: cholesterol fluPHENAZine (fluPHENAZine 10 mg oral tablet) 1 Tablet(s), Oral, 3 TIMES A DAY fluPHENAZine 10 Miligram, Oral, 3 TIMES A DAY, Indication: Psychosis levoTHYROXINE (levoTHYROXINE 100 mcg (0.1 mg) oral tablet) 1 Tablet(s), Oral, DAILY levoTHYROXINE 100 Microgram, Oral, DAILY, Indication: thyroid metoprolol (metoprolol tartrate 50 mg oral tablet) 1 Tablet(s), Oral, 2 TIMES A DAY metoprolol 50 Miligram, Oral, 2 TIMES A DAY, Indication: HTN

Recommendations

- Beneficial: Nursing staff education regarding methods to obtain accurate medication history
 - Identification of individual managing medications
 - · Patient vs. family member vs. caretaker vs. facility
 - MAR = gold standard for SNF patients
 - Careful consideration historian reliability
 - Verification with multiple sources as needed
 - Ex: Outpatient pharmacy
 - Appropriate handoffs and follow-up if optimal list not obtained upon admission

Recommendations

- Optimal: Dedicated resources to perform medication histories
 - Float nurses trained in medication reconciliation or
 - Pharmacy technicians or
 - Pharmacy interns or
 - ToC pharmacist + above

References

- 1) National Transitions of Care Coalition. Available at www.ntocc.org (Accessed June 1, 2015).
- 2) Viggiano, Theresa, Harold A Pincus, and Stephen Crystal. "Care Transition Interventions in Mental Health." Current Opinion in Psychiatry 25.6 (2012): 551-58. Web.
- 3) Gleason, Kristine M, et al. "Reconciliation of discrepancies in medication histories and admission orders of newly hospitalized patients." American journal of health-system pharmacy 61.16 (2004):1689-1695.
- 4) Hampton, Lee M, Matthew Daubresse, Hsien-Yen Chang, G Caleb Alexander, and Daniel S Budnitz. "Emergency Department Visits by Adults for Psychiatric Medication Adverse Events." JAMA Psychiatry 71.9: 1006-014. Web.